SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-026349
Filing Date
2024-07-05
Accepted
2024-07-05 16:10:13
Documents
14
Period of Report
2024-07-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39898
  Complete submission text file 0001493152-24-026349.txt   257306

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bctx-20240703.xsd EX-101.SCH 3750
3 XBRL DEFINITION FILE bctx-20240703_def.xml EX-101.DEF 26591
4 XBRL LABEL FILE bctx-20240703_lab.xml EX-101.LAB 36631
5 XBRL PRESENTATION FILE bctx-20240703_pre.xml EX-101.PRE 25215
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5708
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241102716
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)